Long-term Benefits of Circumcision for HIV Prevention
- Details
- Category: Circumcision
- Published on Thursday, 11 March 2010 00:00
- Written by Liz Highleyman
Adult male circumcision continued to offer men a high degree of protection against HIV infection after nearly 5 years, according to long-term follow-up data from a study in Uganda presented at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) last week in Boston. A related study found that elective adult circumcision reduced the occurrence of genital ulcers by about half, though it had no significant effect on genital herpes.
CROI 2011: Low Vitamin D Levels Less Likely with Rilpivirine than Efavirenz
- Details
- Category: Bone Loss
- Published on Thursday, 18 March 2010 00:00
- Written by Matt Sharp
HIV positive people who use antiretroviral regimens containing the investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (TMC278) saw smaller changes in their vitamin D levels and were less likely to develop severe deficiency than people taking efavirenz, according to a presentation at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) this month in Boston.
CROI 2011: Safety and Acceptability of Tenofovir Gel and Tablets for Pre-exposure Prevention
- Details
- Category: HIV Prevention
- Published on Friday, 04 March 2011 00:00
- Written by Paul Dalton
A vaginal microbicide gel containing tenofovir was found to be generally well tolerated and acceptable by American and African women, though some study participants preferred taking a pill for HIV pre-exposure prophylaxis (PrEP), according to study findings reported this week at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) in Boston. A related study found that the vaginal gel was not suitable for rectal use, and researchers are working on a more tolerable formulation.
CROI 2011: Safety and Acceptability of Tenofovir Gel and Tablets for Pre-exposure Prevention
- Details
- Category: HIV Prevention
- Published on Friday, 04 March 2011 00:00
- Written by Paul Dalton
A vaginal microbicide gel containing 1% tenofovir (Viread) was found to be generally well tolerated and acceptable by American and African women, though some study participants preferred taking a pill for HIV pre-exposure prophylaxis (PrEP), according to study findings reported this week at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) in Boston. A related study found that the vaginal gel was not optimal for rectal use, and researchers are working on a more suitable formulation.
CROI 2011: FDA Safety Review Does Not Find Abacavir-Heart Attack Link
- Details
- Category: Cardiovascular Disease
- Published on Friday, 04 March 2011 08:56
- Written by FDA
A meta-analysis by researchers from the U.S. Food and Drug Administration (FDA) adds to the ongoing debate about the association between the NRTI abacavir (Zaigen, also in the Epzicom and Trizivir coformulations) and increased risk of myocardial infarction and other cardiovascular events. The new review of 26 randomized clinical trials, presented as a poster at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) this week in Boston, did not reveal a significant link between abacavir and heart attacks.
More Articles...
- Once-daily Raltegravir Found Less Effective than Twice-Daily Dosing
- CROI 2011: Researchers Report Further Findings from iPrEx PrEP Trial
- CROI 2011: New Tenofovir Pro-drug GS-7340 Looks Good in Early Study
- CROI 2011: Experimental Integrase Inhibitor Dolutegravir Looks Promising for People with Resistant HIV
Web Design and Development by